New Advances in Hyperkalemia Treatment Offer Hope for Heart Patients

Medical News: Understanding Hyperkalemia and Why It Matters
Hyperkalemia, an excess of potassium in the blood, can be a dangerous complication for people with heart conditions, diabetes, or chronic kidney disease. Potassium, a key mineral, helps regulate muscle and nerve function. However, when potassium levels rise too high, it can cause serious heart problems, including arrhythmias and even sudden death. This issue is particularly challenging for patients who rely on medications like renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs) to manage their heart conditions. Unfortunately, these medications, though effective in protecting heart and kidney health, can also increase potassium levels, leading to hyperkalemia.


New Advances in Hyperkalemia Treatment Offer Hope for Heart Patients

For many patients, managing high potassium levels becomes a balancing act - taking effective medications while avoiding dangerously high potassium. This Medical News report highlights recent strategies developed to address hyperkalemia, allowing patients to safely continue essential heart medications.
 
Key Challenges in Managing Hyperkalemia
One of the main challenges in treating patients with cardiovascular diseases is that almost half experience recurrent hyperkalemia episodes, sometimes more than twice a year. This is especially common among older adults and people with multiple health conditions, as they are more vulnerable to shifts in potassium levels due to factors like dehydration, poor kidney function, and medication interactions.
 
Many times, healthcare providers must reduce or stop heart-protecting medications to prevent hyperkalemia, leaving patients without the full benefits of these treatments. This approach often leads to poor disease management and increases the risk of hospitalization and complications. However, new treatments and guidelines now offer ways to manage potassium without sacrificing heart protection.
 
Innovative Treatments for Hyperkalemia
Recent research has focused on new medications designed specifically to lower potassium levels in patients with heart disease or kidney issues. These medications, called potassium binders, help absorb excess potassium from the digestive tract and lower blood levels effectively.
 
Patiromer and Sodium Zirconium Cyclosilicate (SZC)
Patiromer and SZC are potassium binders approved for managing hyperkalemia. Patiromer works by binding to potassium in the intestines, reducing its absorption and thereby lowering blood levels. This treatment has been particularly useful for patients with chronic kidney disease, who often have trouble managing potassium naturally. The AMBER trial found that patiromer allowed more patients to continue taking essential medications like spironolactone while minimizing potassium spikes.
 
SZC, another potassium binder, acts faster than patiromer, reducing potassium levels within one to two hours. A major study, the HARMONI ZE trial, showed that SZC effectively lowered potassium levels in patients with heart failure and kidney disease, maintaining safe levels over time.
 
Both drugs have shown promise in enabling patients to stay on RAASi and MRA medications without the risk of elevated potassium. While gastrointestinal side effects like constipation or nausea are common, these drugs are generally well tolerated. Notably, SZC does not affect calcium or magnesium levels, making it safer for long-term use.
 
Other Approaches to Reduce Hyperkalemia Risk
 
Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)
SGLT2 inhibitors, commonly used in diabetes management, have emerged as a potential solution for managing hyperkalemia. In patients with heart failure and kidney disease, these drugs not only help with blood sugar but also reduce potassium levels. A meta-analysis of trials with SGLT2 inhibitors indicated that these drugs lowered the risk of severe hyperkalemia by 16% across various patient groups, including those with heart failure or diabetes. This dual benefit has led to increased use of SGLT2 inhibitors among patients needing strict potassium control.
 
Finerenone: A New MRA with Fewer Potassium Risks
Finerenone, a newer type of MRA, shows promise in reducing the risk of hyperkalemia compared to older MRAs. Unlike traditional steroid-based MRAs, finerenone has a lower risk of causing elevated potassium. In clinical trials, including the FIDELIO-DKD and FIGARO-DKD trials, finerenone led to fewer cases of serious hyperkalemia. Although hyperkalemia risk still exists, finerenone has become an option for patients who struggle with high potassium levels on other MRAs.
 
 Adjusting RAASi and MRA Treatments with Diuretics
To lower potassium levels, doctors sometimes prescribe diuretics (water pills) alongside RAASi or MRA medications. Diuretics help the kidneys excrete more potassium, reducing blood levels. In particular, thiazide diuretics are often used in combination with RAASi for patients with hypertension, as they counteract the potassium-raising effects of these medications. However, managing diuretics requires close monitoring, as they can cause dehydration or low sodium levels, especially in older patients.
 
Practical Guidelines and Recommendations
Recognizing the complexity of managing hyperkalemia, leading health organizations have updated their guidelines to help healthcare providers choose the best treatment plans for patients with cardiovascular and kidney disease. The European Society of Hypertension, the American College of Cardiology, and Kidney Disease: Improving Global Outcomes (KDIGO) have all issued guidance on using potassium binders to manage hyperkalemia.
 
The KDIGO guidelines, for instance, recommend that healthcare providers consider potassium-lowering treatments like patiromer or SZC for patients with blood potassium levels above 5.0 mmol/L, especially if they are on RAASi or MRAs. The goal is to maintain essential heart medications without compromising patient safety.
 
To manage potassium levels effectively, healthcare providers need to monitor patients closely and personalize treatments based on their unique health profiles. For some patients, switching to finerenone or adding SGLT2 inhibitors may offer a safer alternative to traditional MRAs.
 
Conclusion: Hope for Safer Heart Treatment
The recent advancements in hyperkalemia management have provided a safer way for patients with heart disease, hypertension, or kidney issues to benefit from life-saving medications without the fear of high potassium levels. By using potassium binders like patiromer and SZC, and incorporating SGLT2 inhibitors and finerenone, healthcare providers can better manage potassium levels and help patients continue essential treatments.
 
Ultimately, the availability of these new treatment options means fewer patients will need to stop their medications due to hyperkalemia concerns, leading to better overall outcomes and improved quality of life. However, ongoing research is crucial to fully understand the long-term benefits of these treatments, especially as more patients are diagnosed with chronic conditions requiring careful potassium management.
 
The study findings were published in the peer-reviewed European Journal of Internal Medicine.
https://www.sciencedirect.com/science/article/pii/S0953620524004345
 
For the latest on Hyperkalemia, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/phase-iii-harmonize-global-trial-of-lokelma-confirms-efficacy-in-maintaining-normal-potassium-levels-in-asian-patients-with-hyperkalaemia
 
https://www.thailandmedical.news/news/new-approach-for-treating-hypertension